The effect of selective estrogen receptor modulators on parameters of the hypothalamic-pituitary-gonadal axis

Annals of the New York Academy of Sciences

Volumn 949, Issue , 2001, Pages 251-258

  Plouffe Jr , Leo ^a   Siddhanti, Suresh ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Hypothalamic pituitary gonadal axis; Males; Postmenopause; Premenopause; Selective estrogen receptor modulators

Indexed keywords

4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ACOLBIFENE; ARZOXIFENE; CLOMIFENE; DROLOXIFENE; ESTRADIOL; ESTROGEN RECEPTOR; FOLLITROPIN; GONADORELIN; LASOFOXIFENE; LUTEINIZING HORMONE; PROLACTIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE; TOREMIFENE;

BREAST CANCER; CONFERENCE PAPER; DRUG EFFECT; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; OSTEOPOROSIS; OVULATION INDUCTION; POSTMENOPAUSE; PREMENOPAUSE;

EID: 0035680470     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb04029.x     Document Type: Conference Paper

References (26)

1. Raloxifene: A selective estrogen receptor modulator
2. Selective estrogen receptor modulators (SERMs) in clinical practice
3. LY353381 HCl: A novel raloxifene analog with improved SERM potency and efficacy in vivo
4. Prevention of development of dimethylbenz(a)anthracene (DMBA)-induced mammary tumors in the rat by the new nonsteroidal antiestrogen EM-800 (SCH57050)
5. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat
6. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium
7. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus
8. The menstrual cycle: An integrative view
9. Comparison of pharmacodynamic properties of various estrogen formulations
10. Induction of ovulation with MRL/41
11. Ovulation induction: Clomiphene citrate
12. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles
13. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue
14. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients
15. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure
16. Effects of raloxifene on bone mineral density, serum cholesterol concentration, and uterine endometrium in postmenopausal women
17. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
18. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients
19. Sex hormones in postmenopausal women with breast cancer on tamoxifen
20. Endocrine mechanism of action of toremifene at the level of the central nervous system in advanced breast cancer patients
21. Influence of droloxifene (3hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen legels in postmenopausal breast cancer patients
22. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer
23. Use of clomiphene citrate in the treatment of men with high sperm chromatin stability
24. Hormonal evaluation in idiopathic oligozoospermia: Correlation with response to clomiphene citrate therapy and sperm motility
25. Treatment of idiopathic and postvaricocelectomy oligozoospermia with oral tamoxifen citrate
26. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia